Compare MRVI & RPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRVI | RPC |
|---|---|---|
| Founded | 2014 | 1992 |
| Country | United States | United States |
| Employees | N/A | 326 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 905.4M |
| IPO Year | 2020 | N/A |
| Metric | MRVI | RPC |
|---|---|---|
| Price | $6.59 | $8.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.13 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 2.9M | 472.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.96% |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $185,743,000.00 | N/A |
| Revenue This Year | $12.54 | $16.82 |
| Revenue Next Year | $7.87 | $15.80 |
| P/E Ratio | ★ N/A | $53.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $6.79 |
| 52 Week High | $7.44 | $9.32 |
| Indicator | MRVI | RPC |
|---|---|---|
| Relative Strength Index (RSI) | 54.97 | 55.48 |
| Support Level | $3.36 | $7.54 |
| Resistance Level | N/A | $8.78 |
| Average True Range (ATR) | 0.38 | 0.34 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 45.65 | 69.53 |
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue mainly comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.